<DOC>
	<DOC>NCT00259311</DOC>
	<brief_summary>The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as depression).</brief_summary>
	<brief_title>Efficacy Study of LY2422347 to Treat Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>must have been diagnosed with primary insomnia must not be significantly overweight must be able to visit the study doctor's office once every 2 weeks for 8 weeks and willing to use a handheld electronic device as a sleep diary every day must be able to read and speak in English and be able to see well enough to use the handheld electronic device the patient's answer to the question "During the past month, how would you rate your sleep quality overall?" must be either "Very Bad" or "Fairly Bad" cannot have a clinically significant and/or uncontrolled condition or other significant ailment including restless leg syndrome (RLS) or periodic limb movement disorder (PLMD) cannot have obstructive sleep apnea (OSA), or be considered by the study doctor to have probable OSA based upon patient history and physical examination cannot be currently using antidepressants, antipsychotics, stimulants, antihistaminics, or other medications that are known to effect sleep cannot have a current or previous major psychiatric disorder (other than insomnia) such as depression, schizophrenia, bipolar disorder, social anxiety, or another psychotic disorder.</criteria>
	<gender>All</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>